Biosimilars in India; current status and future perspectives-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biosimilars in India; current status and future perspectives

Published:2019 Issue:1 Volume:11 Page:12
ISSN:0975-7406
Container-title:Journal of Pharmacy And Bioallied Sciences
language:en
Short-container-title:J Pharm Bioall Sci

Author:

Meher BikashR,Balan Sakthi,Mohanty RashmiR,Jena Monalisa,Das Smita

Publisher

Medknow

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,Bioengineering

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment;Applied Health Economics and Health Policy;2024-07-01

2. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries;PLOS Global Public Health;2024-07-01

3. A Regulatory Perspective on Biosimilar Medicines;Pharmaceutics;2024-02-25

4. Enhancing access to treatment for Gaucher disease in India: The need for indigenous manufacturing;Journal of Biosciences;2024-02-20

5. Mechanism of Biosimilars for the Treatment of Cancer;Biosimilars for Cancer Treatment;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP